Maintaining adherence is challenging for chronic conditions such as multiple sclerosis. For disease-modifying therapies requiring regular subcutaneous self-administration, autoinjector devices offer a safe, simple, modifiable, and reliable method of self-administration that may help overcome injection-related factors interfering with comfort and treatment adherence.

Single-arm trials and patient surveys have indicated that autoinjectors are helpful for treatment and improve adherence; however, real-world evidence on this topic is lacking.

In the current real-world study, we find that following the introduction of BETACONNECT®, an autoinjector for interferon-β-1b, adherence to interferon-β-1b indexed by medication possession ratio, and persistence, were higher than for interferon-β-1a, another therapy requiring regular subcutaneous self-administration without an autoinjector.